References
- Wysowski DK, Governale LA, Swann J. Trends in out-patient prescription drug use and related costs in the US 1998-2003. Pharmacoeconomics 2006; 24:233–236.
- Dal Pan GJ. Office of Surveillance and Epidemiology Center for Drug Evaluation and Research June 29,2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM175767.pdf. Accessed October 27, 2012.
- Michna E, Sheng M, Korves C, Dahl JL. Removal of opioid/acetaminophen combination prescription medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications. Pain Medicine 2010; 11:3269–378.
- IMS HEALTH. IMS National Prescription AuditTM. Available from: http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-Line%20Market%20Data%20&%20Trends/2011%20Top-line%20Market%20Data/Top_Products_by_RX.pdf. Accessed June 2013
- Bronstein AL, Spyker DA, Cantilena LR, Green JL, Rumack BH, Dart RC. 2010 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 28th annual report. Clin Toxicol 2011; 49:910–941.
- Karwoski CB. Briefing document: Acetaminophen containing products and hepatotoxicity. Division of Drug Risk Evaluation. August 2 2002. Available from: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3882b1_02_C-Acetaminophen%20Hepatotoxicity.pdf. Accessed October 2012
- Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis 2007; 11: 525–548.
- O’Grady JG, Alexander GJM, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439–443.
- Drug Abuse Warning Network, Substance Abuse and Mental Services. http://www.samhsa.gov/data/2k12/DAWN2k10/DAWN2k10-Glossary.htm. Accessed June 2013
- NPDS Reference manual 2009. Available from: http://www.aapcc.org/data-system/. Accessed May 2013.
- Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159–174.
- Reynolds KM, Green RC, Dart RC, Bucher-Bartelson B, Khatri V. Overall quality of poison center data for acetaminophen-containing products is high, but coding of product-specific fields needs improvement. Clin Toxicol 2012; 50: 620. (abstract)
- Ostapowich G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a retrospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137:947–954.
- Reuben A, Koch DG, Lee WM; Acute Liver Failure Study group. Drug-induced acute liver failure: results of a US multicenter, prospective study. Hepatology 2010; 52:2065–2076.
- Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al.; Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42:1364–1372.
- Lee WM. Drug-induced hepatotoxicity. NEJM 2003; 349:474–485.
- O’Brien CP. Drug addiction. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill; 2011:652–654.
- Woodcock J. FDA Center for Drug Evaluation and Research. November 2010 Memorandum. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM234349.pdf. Accessed May 2013.
- Wolf MS, King J, Jacobson K, Di Francesco L, Bailey SC, Mullen R, et al. Risk of unintentional overdose with non- prescription acetaminophen products. J Gen Intern Med 2012; 27: 1587–1593.
- Woodcock J, Griffin JP, Behrman RE. Development of novel combination therapies. New Engl J Med 2011; 364:985–987.
- Podolsky SH, Greene JA. Combination drugs- hype, harm and hope. New Engl J Med 2011; 365:488–491.
- FDA. Available from: http://www.regulations.gov/#!documentDetail;D = FDA-2011-N-0021-0001 . Accessed December 2012
- Doyon S, Fowler D. Comparison of exposure fatalities from the medical examiner's office and the poison center. Clin Toxicol 2012; 50: 645 (abstract)